The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis

M Vališ, A Achiron, HP Hartung, J Mareš, V Tichá… - Drugs in R&D, 2023 - Springer
Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central
nervous system (CNS). Currently, MS treatment is limited to several Food and Drug …

Immune checkpoints: new insights into the pathogenesis of thyroid eye disease

X Shu, Y Shao, Y Chen, C Zeng, X Huang… - Frontiers in …, 2024 - frontiersin.org
Thyroid eye disease (TED) is a disfiguring autoimmune disease characterized by changes in
the orbital tissues and is caused by abnormal thyroid function or thyroid-related antibodies. It …

Experimental analysis of tear fluid and its processing for the diagnosis of multiple sclerosis

V Tomečková, S Tkáčiková, I Talian, G Fabriciová… - Sensors, 2023 - mdpi.com
A pilot analysis of the tear fluid of patients with multiple sclerosis (MS) collected by glass
microcapillary was performed using various experimental methods: liquid chromatography …

[HTML][HTML] Effect of anti-COVID-19 drugs on patients with cancer

W Huang, W Liu, T Yu, Z Zhang, L Zhai… - European Journal of …, 2024 - Elsevier
The clinical treatment of patients with cancer who are also diagnosed with coronavirus
disease (COVID-19) has been a challenging issue since the outbreak of COVID-19 …

A narrative review of neuro-ophthalmologic disease in African Americans and Hispanics with multiple sclerosis

L Tardo, A Salter, M Truong-Le… - … in Chronic Disease, 2023 - journals.sagepub.com
Multiple sclerosis (MS) is the most common non-traumatic cause of disability in young
people, with vision loss in the disease representing the second largest contributor to …

[HTML][HTML] Siponimod-associated cystoid macular edema without known risk factors

MY Kim, A Alkhabaz, SJ Smith, YJ Liao - American Journal of …, 2024 - Elsevier
Purpose This case report highlights the importance of monitoring ocular health for patients
starting on siponimod treatment, a sphingosine-1-phosphate receptor modulator, for …

Siponimod-related bilateral cystoid macular oedema and intravenous fluorescein angiographic findings in a patient with stable proliferative diabetic retinopathy …

WF Foos, C Culp, M Asahi… - BMJ Case Reports CP, 2022 - casereports.bmj.com
Siponimod is a sphingosine-1-phosphate receptor modulator used as disease-modifying
therapy for relapsing-remitting multiple sclerosis similar to Fingolimod which has been …

Ponesimod-associated macular edema: onset and resolution

H Singh, K Patel, A Port - Journal of VitreoRetinal Diseases, 2024 - journals.sagepub.com
Purpose: To present a patient with cystoid macular edema (CME) associated with
ponesimod use and offer suggestions for the management of this condition. Methods: A case …

[PDF][PDF] Eine Übersicht über neuro-ophthalmologische Erkrankungen bei Afroamerikanern und Hispanics mit multipler Sklerose

L Tardo, A Salter, M Truong-Le, L Horton… - Kompass …, 2023 - karger.com
Multiple Sklerose (MS) ist die häufigste nichttraumatische Ursache für Behinderungen bei
jungen Menschen, wobei der Verlust des Sehvermögens bei dieser Krankheit den …

[PDF][PDF] Experimental Analysis of Tear Fluid and their Processing for the Diagnosis of Multiple Sclerosis

V Tomeckova - Clin Surg, 2023 - clinicofsurgery.org
A pilot analysis of the tear fluid of patients with multiple sclerosis (MS) collected by glass
microcapillary was performed using various experimental methods: liquid chromatography …